MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Seres Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.42−0.04 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $23.59M
- P/E (TTM)
- –
- Dividend yield
- –
Seres Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 19 | Q3 19 | Q2 19 | Q1 19 | Q4 18 | Q3 18 | Q2 18 | Q1 18 | Q4 17 | Q3 17 | Q2 17 | Q1 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue - Related Party [Member] | $5.28M | $4.84M | $10.45M | $6.62M | $10.20M | $8.68M | $4.27M | $3.77M | $3.06M | $23.02M | $3.01M | $3.02M | 100.0% | -48.2% |
| Grant Revenue [Member] | – | – | – | – | – | – | $341.00K | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Seres Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.